AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Stars over Athens: The who’s who at Calcalist's first Israel-Greece conference
3
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
4
Claroty veterans launch Twine with $12M in Seed funding from Dell and Wiz founders to deploy AI cyber workers
5
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
More news

Kåre Schultz

20 stories about Kåre Schultz
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Quarterly Report Meets Analyst Expectations

07.11.19|Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
קאר שולץ מנכל טבע

Rivals' Earning Reports Should Have Teva's Shareholders Worried

05.08.19|Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Where is Kåre Schultz?

17.07.19|Sophie Shulman
The Danish CEO was drafted to save Teva straight off the successful turnaround of pharma company Lundbeck. Since then, the Israeli company’s market cap dropped by 66%, but Schultz has stayed mum
קאר שולץ מנכל טבע

Teva Trending Down Following Underwhelming Second Quarter Revenues

02.08.18|Dror Reich
On Thursday, the generic drugmaker announced revenues that fell slightly short of analyst consensus
מטה טבע פתח תקווה

Building on Strong First Quarter, Teva Raises 2018 Outlook

03.05.18|Lilach Baumer and Dror Reich
The company reported a 10% decrease in revenues compared to 2017, largely due to North American Copaxone troubles, but beat analyst expectations
מנכ"ל טבע החדש קור שולץ 2

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18|Dror Reich
In a meeting with investors in Israel, CEO Kåre Schultz said the Washington offices were used mainly by lobbyists, for which Teva has no further need
מנכ"ל טבע החדש קור שולץ 2

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer
The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
תלמידים ב בית ספר לומדים מבחן בגרות מתמטיקה

CTech’s Daily Israeli Tech News Roundup

03.01.18|CTech
Israel to train high schoolers for big data intelligence jobs. Israeli-linked tech deals, IPOs at an all-time high. Lab-grown meat startup raises $3 million
מנכ"ל טבע החדש קור שולץ 2

As U.S. Domestic Issuer, Teva Reveals Top Stock Owners

03.01.18|Dror Reich
Kåre Schultz, the newly-appointed CEO of generic drugmaker Teva Pharmaceutical Industries Ltd., is one of Teva's largest shareholders, a Wednesday filing to the U.S. Securities and Exchange Commission revealed
עובדי טבע חוסמים את אזור הכניסה ל ירושלים

Teva CEO to Netanyahu: Layoffs will Proceed as Planned

19.12.17|Omri Milman
In a statement, the company said it rejects the Israeli government’s appeal to withdraw cutback plans
עובדי טבע פתח תקווה מפגינים על ציר ז'בוטינסקי

CTech’s Daily Israeli Tech News Roundup

17.12.17|CTech
Teva might have been better off as a smaller company, new CEO says. Tel Aviv airport, stock market open as in support of Teva employees ends. A new blockchain powered juggernaut stock arrives on the Tel Aviv Stock Exchange
אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
מנכ"ל טבע החדש קור שולץ

Teva Might Have Been Better Off as a Smaller Company, new CEO Says

17.12.17|Dror Reich
The generic drugs powerhouse is now carrying a $34.7 billion debt—a result of a $40.5 acquisition of Actavis. New CEO Kåre Schultz presented a detailed restructuring plan on Thursday
מנכ"ל טבע החדש קור שולץ 2

Teva to Let Go 14,000 Employees Over the Next Two Years

14.12.17|Lilach Baumer
The company released a statement detailing its reconstruction plan Thursday. CEO Kåre Schultz elaborated on the plan during a call with investors
פסקל סוריו מנכ"ל AstraZeneca

Once Future CEO Could have Taken Teva on a Different Path

14.12.17|Lilach Baumer, Golan Hazani, and Orr Hirschauge
AstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
אבי ניסנקורן מסיבת עיתונאים טבע פיטורים

Israeli Union Leader Calls for General Strike on Expected Teva Cutback Reports

14.12.17|Dror Reich, Sefi Krupsky, and Adrian Filut
On Wednesday, Calcalist reported Teva intends to terminate over half of its employees in Israel in the next months
מנכ"ל טבע החדש קור שולץ 2

Teva to Cut Around Half of Israeli Workforce, Outsource Operations

13.12.17|Dror Reich
An internal document reviewed by Calcalist reveals the troubled drugmaker's detailed domestic cost-cutting plans
מפעל טבע טק ב רמת חובב

Teva to Cut Jobs, Shut Down Some Israeli Operations

13.12.17|Dror Reich and Sefi Krupsky
On Thursday, the troubled drugmaker is expected to unveil its cutback plan. At its center is extensive layoffs and the reorganization and divestment of non-core assets
יצחק פטרבורג

Former Chairman Yitzhak Peterburg Leaves Teva

13.12.17|Lilach Baumer
Mr. Peterburg was the troubled drugmaker's interim CEO between February and November 1, when Kåre Schultz took helm
מנכ"ל טבע החדש קור שולץ

New CEO Steers Teva Back to Generics

28.11.17|Golan Hazani and Dror Reich
A reorganization plan announced by the company Monday would see the troubled drugmaker return to its core competencies, despite market pressures
More Articles